NCT06501586

Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of SGB-3908 After a Single Administration in Healthy Subjects and Mildly Hypertensive Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Suzhou Sanegene Bio Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects. The study will be a single ascending dose (SAD) phase.

Conditions

• Hypertension,Essential

Interventions

Type	Name	Description
DRUG	SGB-3908	SGB-3908 for sc injection
OTHER	SGB-3908-Matching placebo	Normal saline (0.9% NaCl) matching volume of SGB-3908 doses will be administered

Timeline

• Start date: 2024-07-31
• Primary completion: 2025-04-07
• Completion: 2025-12-15
• First posted: 2024-07-15
• Last updated: 2026-02-10

Locations

1 site across 1 country: China